Encompass Health (NYSE:EHC) Price Target Cut to $62.00 by Analysts at Credit Suisse Group
Encompass Health (NYSE:EHC) Price Target Cut to $62.00 by Analysts at Credit Suisse Group
Encompass Health (NYSE:EHC – Get Rating) had its target price cut by Credit Suisse Group from $63.00 to $62.00 in a research note published on Wednesday, Marketbeat Ratings reports. They currently have an outperform rating on the stock.
据市场评级公司报道，在周三发布的一份研究报告中，瑞士信贷集团将Enfinass Health(纽约证券交易所代码：EHC-GET评级)的目标价从63.00美元下调至62.00美元。他们目前对该股的评级为跑赢大盘。
Several other analysts also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Encompass Health from $80.00 to $62.00 in a report on Wednesday, August 3rd. Truist Financial reduced their price target on shares of Encompass Health from $75.00 to $65.00 and set a buy rating on the stock in a report on Monday, August 8th. Barclays reduced their price target on shares of Encompass Health from $80.00 to $63.00 and set an overweight rating on the stock in a report on Thursday, August 4th. Raymond James reduced their price target on shares of Encompass Health from $70.00 to $65.00 and set a strong-buy rating on the stock in a report on Thursday, August 4th. Finally, Royal Bank of Canada cut their price objective on shares of Encompass Health from $82.00 to $66.00 in a research report on Wednesday, August 24th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Encompass Health has an average rating of Buy and an average price target of $70.00.
其他几位分析师最近也发布了有关该股的报告。德意志银行Aktiengesellschaft在8月3日星期三的一份报告中将Enneass Health的目标价从80.00美元下调至62.00美元。Truist Financial在8月8日星期一的一份报告中将Enneass Health的目标价从75.00美元下调至65.00美元，并对该股设定了买入评级。巴克莱在8月4日周四的一份报告中将Enneass Health的目标价从80.00美元下调至63.00美元，并对该股设定了增持评级。雷蒙德·詹姆斯在8月4日(星期四)的一份报告中将Enneass Health的目标价从70.00美元下调至65.00美元，并对该股设定了强力买入评级。最终，加拿大皇家银行在8月24日星期三的一份研究报告中将其股票目标价从82.00美元下调至66.00美元。一位分析师对该股的评级为持有，8位分析师给出了买入评级，一位分析师给出了强烈的买入评级。根据MarketBeat的数据，Enoverass Health的平均评级为买入，平均目标价为70.00美元。
Encompass Health Stock Down 2.3 %
包括健康类股下跌2.3%
EHC stock opened at $48.87 on Wednesday. The company has a market cap of $4.88 billion, a P/E ratio of 14.94, a P/E/G ratio of 2.43 and a beta of 1.02. Encompass Health has a 52 week low of $44.33 and a 52 week high of $78.31. The company's 50-day moving average price is $50.78 and its 200 day moving average price is $59.30. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 1.29.
周三，EHC股价开盘报48.87美元。该公司市值为48.8亿美元，市盈率为14.94倍，市盈率为2.43倍，贝塔系数为1.02倍。Entainass Health的52周低点为44.33美元，52周高位为78.31美元。该公司的50日移动均线价格为50.78美元，200日移动均线价格为59.30美元。该公司的流动比率为1.24，速动比率为1.24，债务权益比率为1.29。
Encompass Health Cuts Dividend
包括削减股息的医疗保健
The business also recently declared a quarterly dividend, which will be paid on Monday, October 17th. Investors of record on Monday, October 3rd will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 1.23%. The ex-dividend date is Friday, September 30th. Encompass Health's dividend payout ratio (DPR) is 34.25%.
该公司最近还宣布了季度股息，将于10月17日(星期一)支付。10月3日(星期一)登记在册的投资者将获得每股0.15美元的股息。这意味着年化股息为0.60美元，收益率为1.23%。除息日为9月30日(星期五)。Enneass Health的股息支付率(DPR)为34.25%。
Insider Buying and Selling
内幕买卖
In related news, CEO Mark J. Tarr sold 20,449 shares of the company's stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $53.25, for a total transaction of $1,088,909.25. Following the completion of the transaction, the chief executive officer now owns 440,895 shares of the company's stock, valued at $23,477,658.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.70% of the stock is currently owned by company insiders.
在相关新闻中，首席执行官马克·J·塔尔在8月17日星期三的一次交易中出售了20,449股公司股票。这些股票的平均价格为53.25美元，总成交金额为1,088,909.25美元。交易完成后，首席执行官现在拥有440,895股公司股票，价值23,477,658.75美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站。公司内部人士目前持有该公司2.70%的股份。
Hedge Funds Weigh In On Encompass Health
对冲基金对Enneass Health的看法
Institutional investors and hedge funds have recently bought and sold shares of the stock. Baupost Group LLC MA grew its stake in Encompass Health by 318.9% during the first quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company's stock worth $213,330,000 after buying an additional 2,283,900 shares during the period. State Street Corp grew its stake in Encompass Health by 5.0% during the first quarter. State Street Corp now owns 2,733,254 shares of the company's stock worth $195,118,000 after buying an additional 130,504 shares during the period. Victory Capital Management Inc. grew its stake in Encompass Health by 40.0% during the second quarter. Victory Capital Management Inc. now owns 2,146,910 shares of the company's stock worth $120,335,000 after buying an additional 613,547 shares during the period. Bank of New York Mellon Corp grew its stake in Encompass Health by 33.3% during the first quarter. Bank of New York Mellon Corp now owns 2,099,763 shares of the company's stock worth $149,314,000 after buying an additional 524,766 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in Encompass Health by 88.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,685,880 shares of the company's stock worth $94,494,000 after buying an additional 792,813 shares during the period. Institutional investors and hedge funds own 93.07% of the company's stock.
机构投资者和对冲基金最近买卖了该股的股票。今年第一季度，Baupost Group LLC MA在Enneass Health的持股增加了318.9%。Baupost Group LLC MA现在拥有300万股该公司股票，价值213,330,000美元，在此期间又购买了2,283,900股。道富集团在第一季度持有的Enneass Health股份增加了5.0%。道富银行目前持有2,733,254股该公司股票，价值195,118,000美元，在此期间又购买了130,504股。胜利资本管理公司在第二季度增持了40.0%的Enneass Health股份。胜利资本管理公司现在持有该公司2,146,910股股票，价值120,335,000美元，在此期间又购买了613,547股。今年第一季度，纽约梅隆银行(Bank Of New York Mellon Corp)在Enneass Health的持股增加了33.3%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有该公司2,099,763股股票，价值149,314,000美元，在此期间又购买了524,766股。最后，马云金融服务公司在第二季度增持了88.8%的Enneass Health股份。马云目前持有该公司1,685,880股股票，价值94,494,000美元，在此期间又购买了792,813股。机构投资者和对冲基金持有该公司93.07%的股票。
About Encompass Health
关于包罗万象健康
(Get Rating)
(获取评级)
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Enneass Health Corporation在美国提供基于设施和以家庭为基础的急性后保健服务。该公司在两个领域开展业务，住院康复以及家庭健康和临终关怀。住院康复部分为正在康复的患者提供住院和门诊的专门康复治疗，这些疾病包括中风和其他神经疾病、心脏和肺部疾病、脑和脊髓损伤、复杂的骨科疾病和截肢。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Encompass Health (EHC)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
- 免费获取StockNews.com关于Enfass Health(EHC)的研究报告
- 对塔吉特来说，最糟糕的时期可能已经过去，但这只股票买起来安全吗？
- 这些液态天然气股票准备好上行了吗？
- 内部人士正在买入的两只有趣的股票
- 诺华在避险市场中仍是一只冒险的股票
- 通用磨坊：波动性更小、回报更高
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.
接受《包罗万象健康日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对Enneass Health及相关公司评级的每日简要摘要。